US2019031686A1PendingUtilityA1
Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
Est. expiryMay 9, 2031(~4.8 yrs left)· nominal 20-yr term from priority
Inventors:Kenneth W. BairTimm R. BaumeisterAlexandre Joseph BuckmelterKarl H. ClodfelterBingsong HanJudith D. KuntzJian LinDominic ReynoldsChase C. SmithZhongguo WangXiaozhang Zheng
A61P 37/08A61P 9/10A61P 37/02A61P 3/10A61P 43/00A61P 9/00A61P 35/02A61P 25/28A61P 25/00A61P 35/00A61P 3/00A61P 31/22A61P 31/12A61P 31/18A61P 29/00A61K 31/5377C07D 513/04C07D 215/48A61K 45/06A61K 31/4709A61P 11/06A61K 31/497A61P 13/12A61P 11/00C07D 519/00C07D 495/04C07D 471/04A61K 31/4375A61P 19/02A61K 31/4545A61P 17/06A61P 19/10A61K 31/437A61P 1/00C07D 491/048A61P 17/00A61K 31/4365
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below:
Claims
exact text as granted — not AI-modified1 - 28 . (canceled)
29 . A compound of Formula II:
or a pharmaceutically acceptable salt thereof,
wherein,
W is —C(O)—;
R is aryl or bicyclic heteroaryl;
wherein said heteroaryl contains 1, 2, or 3 heteroatoms independently selected from N, S, and O, with the proviso that no two adjacent ring heteroatoms are both S or both O; and
wherein each of said aryl or heteroaryl is either unsubstituted or substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl, (amino)alkoxy, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CF 3 , —CHF 2 , —CH 2 F, alkyl, alkoxy, hydroxyl, hydroxyalkyl, (alkoxyalkyl)amino, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
G is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;
wherein each of said aryl, heteroaryl, heterocycloalkyl and cycloalkyl is either unsubstituted or substituted with 1, 2, 3, or 4 substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl, (amino)alkoxy, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CF 3 , —CHF 2 , —CH 2 F, alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxyalkyl, aryloxy, (alkoxyalkyl)amino, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
R 1 and R 2 are the same or they are different, and are independently selected from H, C 1 to C 7 alkyl, C 1 to C 7 alkoxy, C 1 to C 4 hydroxyalkyl, aryl, heteroaryl, heterocycloalkyl and cycloalkyl, and
wherein heteroatoms of said heteroaryl and heterocycloalkyl are independently selected from one or more N, O and S, with the proviso that no two adjacent ring heteroatoms are both S or both O; and
wherein R 1 and R 2 are each unsubstituted or substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl, (amino)alkoxy, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CF 3 , —CHF 2 , —CH 2 F, alkyl, hydroxyalkyl, alkoxy, hydroxyl, hydroxyalkyl, carboxy, (alkoxyalkyl)amino, alkylamine, aminocarbonyl, —CHO, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
R 3 is H; and
n is 4, 5, or 6;
wherein the compound of Formula II is obtained by a process comprising a step of treating an acid:
with an amine:
in the presence of a base.
30 . The compound of claim 29 , wherein the acid is:
31 . The compound of claim 30 , wherein the process of obtaining the compound of Formula II further comprises addition of a coupling agent.
32 . The compound of claim 31 , wherein the coupling agent is EDCI, HATU, or HOBt, and the base is K 2 CO 3 , Cs 2 CO 3 , DIEA, NaOH, or KOH.
33 . The compound of claim 29 , wherein the acid is:
34 . The compound of claim 33 , wherein the base is TEA.
35 . A composition comprising a compound of Formula II:
or a pharmaceutically acceptable salt thereof,
wherein,
W is —C(O)—;
R is aryl or bicyclic heteroaryl;
wherein said heteroaryl contains 1, 2, or 3 heteroatoms independently selected from N, S, and O, with the proviso that no two adjacent ring heteroatoms are both S or both O; and
wherein each of said aryl or heteroaryl is either unsubstituted or substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl, (amino)alkoxy, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CF 3 , —CHF 2 , —CH 2 F, alkyl, alkoxy, hydroxyl, hydroxyalkyl, (alkoxyalkyl)amino, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
G is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;
wherein each of said aryl, heteroaryl, heterocycloalkyl and cycloalkyl is either unsubstituted or substituted with 1, 2, 3, or 4 substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl, (amino)alkoxy, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CF 3 , —CHF 2 , —CH 2 F, alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxyalkyl, aryloxy, (alkoxyalkyl)amino, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
R 1 and R 2 are the same or they are different, and are independently selected from H, C 1 to C 7 alkyl, C 1 to C 7 alkoxy, C 1 to C 4 hydroxyalkyl, aryl, heteroaryl, heterocycloalkyl and cycloalkyl, and
wherein heteroatoms of said heteroaryl and heterocycloalkyl are independently selected from one or more N, O and S, with the proviso that no two adjacent ring heteroatoms are both S or both O; and
wherein R 1 and R 2 are each unsubstituted or substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl, (amino)alkoxy, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CF 3 , —CHF 2 , —CH 2 F, alkyl, hydroxyalkyl, alkoxy, hydroxyl, hydroxyalkyl, carboxy, (alkoxyalkyl)amino, alkylamine, aminocarbonyl, —CHO, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
R 3 is H; and
n is 4, 5, or 6;
and further comprising an acid:
36 . The composition of claim 35 , further comprising an amine:
37 . A compound of Formula II:
or a pharmaceutically acceptable salt thereof,
wherein,
W is —C(O)—;
R is aryl or bicyclic heteroaryl;
wherein said heteroaryl contains 1, 2, or 3 heteroatoms independently selected from N, S, and O, with the proviso that no two adjacent ring heteroatoms are both S or both O; and
wherein each of said aryl or heteroaryl is unsubstituted or substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl, (amino)alkoxy, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CF 3 , —CHF 2 , —CH 2 F, alkyl, alkoxy, hydroxyl, hydroxyalkyl, (alkoxyalkyl)amino, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
G is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;
wherein each of said aryl, heteroaryl, heterocycloalkyl and cycloalkyl is either unsubstituted or substituted with 1, 2, 3, or 4 substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl, (amino)alkoxy, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CF 3 , —CHF 2 , —CH 2 F, alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxyalkyl, aryloxy, (alkoxyalkyl)amino, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
R 1 and R 2 are the same or they are different, and are independently selected from H, C 1 to C 7 alkyl, C 1 to C 7 alkoxy, C 1 to C 4 hydroxyalkyl, aryl, heteroaryl, heterocycloalkyl and cycloalkyl, and
wherein heteroatoms of said heteroaryl and heterocycloalkyl are independently selected from one or more N, O and S, with the proviso that no two adjacent ring heteroatoms are both S or both O; and
wherein R 1 and R 2 are each unsubstituted or optionally substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl, (amino)alkoxy, —CONH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , —C(O)NH(aryl), —C(O)N(aryl) 2 , —CF 3 , —CHF 2 , —CH 2 F, alkyl, hydroxyalkyl, alkoxy, hydroxyl, hydroxyalkyl, carboxy, (alkoxyalkyl)amino, alkylamine, aminocarbonyl, —CHO, —N(R 3 )—C(O)-alkyl, —N(R 3 )—C(O)-aryl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
R 3 is H; and
n is 4, 5, or 6;
wherein the compound is obtained by a process comprising treating a first amine:
with a first acid:
in the presence of a first base to give the compound of Formula II.
38 . The compound of claim 37 , wherein the first acid is:
39 . The compound of claim 38 , wherein the process of obtaining a compound of Formula II further comprises addition of a first coupling agent selected from EDCI, HATU, and HOBt.
40 . The compound of claim 39 , wherein the first base is K 2 CO 3 , Cs 2 CO 3 , DIEA, NaOH, and KOH.
41 . The compound of claim 37 , wherein the first acid is:
and the first base is TEA.
42 . The compound of claim 37 , wherein the first amine is obtained by a process of treating a protected amine:
with a strong acid.
43 . The compound of claim 42 , wherein the strong acid is TFA or HCl.
44 . The compound of claim 42 , wherein the protected amine is obtained by a process of treating a second acid:
with a second amine:
in the presence of a second base.
45 . The compound of claim 44 , wherein the second acid is:
46 . The compound of claim 45 , wherein the process of obtaining the protected amine further comprises addition of a second coupling agent.
47 . The compound of claim 46 , wherein the second coupling agent is EDCI, HATU, or HOBt, and the second base is K 2 CO 3 , Cs 2 CO 3 , DIEA, NaOH, or KOH.
48 . The compound of claim 44 , wherein the second acid is:
and the second base is TEA.Join the waitlist — get patent alerts
Track US2019031686A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.